You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
Researchers from the molecular diagnostics firm said their screen could identify a range of variant types to boost the identification of at-risk couples.
Seventy-eight percent of participants had at least one positive carrier screening result and 3.5 percent had a medically actionable secondary finding.
The company delivered 4,621 billable tests during Q1, and billable testing volume was the highest in a quarter in Fulgent's history.
The effort, sponsored by two therapeutics companies, is providing no-cost genetic testing and counseling for people with Duchenne who otherwise couldn't afford it.
The molecular diagnostics company reported total revenues of $56.7 million in the quarter, and saw its testing volume grow 15 percent over Q3 2016.
Carrier screens for cystic fibrosis, fragile X syndrome, and spinal muscular atrophy detected carrier status in one in 20 individuals and led to diagnoses in seven pregnancies.
Core Diagnostics will exclusively offer GenePeeks' preconception screen and advanced analytics platform in 29 states and seven territories in India.
The new deal, which covers Greece and Cyrus, follows a series of partnerships with fertility organizations and a separate distribution pact signed earlier this year.
The multiplexed PCR kit will target mutations associated with cystic fibrosis that are highly prevalent in the US, and the firm is also eyeing the Middle East and Africa.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.